drugset / Trial / NCT00060502

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia

NCT00060502

Phase 2 Completed 73 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.

Timeline

Start
2003-04
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 3 mg/kg
Subject Infliximab Monoclonal antibody 5 mg/kg
Background Gemcitabine Small molecule 1000 mg/m2